Genspera Inc (GNSZ) 0.7700 $GNSZ
GenSpera Inc. - "Glioblastoma Trial Design"
ACCESSWIRE - Thu May 14, 11:05AM CDT
NEW YORK, NY / ACCESSWIRE / May 14, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin
PR Newswire - Wed May 13, 7:09AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today the successful completion of the first stage of an ongoing Phase II study of its lead investigational agent, mipsagargin (G-202), in glioblastoma (brain cancer) and the continuation of enrollment for an expansion phase of the trial. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, Calif., and will evaluate the efficacy, safety and central nervous system (CNS) exposure in patients with recurrent or progressive glioblastoma.
GenSpera Provides Corporate Update
PR Newswire - Mon May 11, 8:03AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today reported its financial results for the three months ended March 31, 2015, and is providing the following corporate update to its shareholders to highlight the company's extensive organizational advances and clinical progress in the first quarter of 2015. GenSpera continues to unlock conventional thinking to conceive, design and develop cancer therapies. GenSpera's unique technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors.
GenSpera Inc. - "Value and Understanding What is Valuable Over Time"
ACCESSWIRE - Thu May 07, 10:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 7, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Dr. Craig A. Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations
PR Newswire - Wed May 06, 8:13AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that the patent application "Injectable Cancer Compositions" has entered the national phase application process in 17 countries and regions, including Europe, Eurasia, Japan, China, Brazil and the United States. When awarded, the resulting patent application will extend the exclusivity period for GenSpera's core intellectual property around its entire platform technology, including its lead drug candidate, mipsagargin, until 2033.
GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen
PR Newswire - Tue Apr 28, 7:10AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,957,016. This patent expands GenSpera's intellectual property portfolio claiming numerous compositions for the company's prodrugs designed to be activated by Prostate Specific Antigen (PSA).
GenSpera Looks Undervalued Compared to Its Peers
ACCESSWIRE - Mon Apr 27, 10:53AM CDT
CORAL GABLES, FL / ACCESSWIRE / April 27, 2015 / For clinical stage biotechs, valuations can be based on hype, speculation, attention from the press or any similar fortuitous circumstance. The only semi-concrete things to go on for price discovery of these securities sweeping financials aside and speaking in broad strokes, are 1) clinical milestones reached (or in other words, chances of eventual approval), 2) potential market size of the approved drug.
CYTR: 4.10 (-0.01), BIND: 5.92 (-0.32), NDRM: 13.10 (-0.01)
GenSpera Inc. - "Recap: Takeaways from Bio Asia"
ACCESSWIRE - Fri Apr 24, 10:10AM CDT
NEW YORK, NY / ACCESSWIRE / April 24, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Dr. Craig A. Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Contends In The Prodrug Space, Reaching Phase 3
Mayer Winkler - at Seeking Alpha - Mon Mar 30, 1:37PM CDT
GenSpera Launches National Investor Relations Program
PR Newswire - Mon Mar 30, 7:10AM CDT
GenSpera Inc. (OTCQB: GNSZ) announced today the selection of PCG Advisory Group (PCG) to launch a comprehensive investor relations initiative for the oncology-focused drug development company. Led by Jeff Ramson, founder and chief executive officer, the PCG team will also be directed by three senior members: Kirin Smith, COO and managing director of investor relations; Jeffrey Hart, managing director of market intelligence; and Sean Leous, CCO. The team will be supported by Carl Mauch, science analyst.
MarketExclusive.com - H.C. Wainwright & Co. Reiterates BUY Rating of GenSpera
ACCESSWIRE - Tue Mar 24, 9:48AM CDT
NEW YORK, NY / ACCESSWIRE / March 24, 2015 / Market Exclusive announces that H.C. Wainwright & Co. continues to rate the shares of GenSpera, Inc. (OTCQB: GNSZ) as Buy with a 12-month price target of $2.00 per share.
GenSpera Inc. - "Why China Matters to GenSpera"
ACCESSWIRE - Mon Mar 23, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / March 23, 2015 / GenSpera Inc. (OTCQB:GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Presents at BIO Asia International Conference
PR Newswire - Tue Mar 17, 7:00AM CDT
GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 12th Annual BIO Asia International Conference on Tuesday, March 24 at 3:15 p.m. JST at the Grand Hyatt in Tokyo, Japan. The presentation will offer an overview of the latest scientific developments of GenSpera's lead investigational agent mipsagargin and the applicability of its innovative mechanism of action in a broad array of oncology treatments.
Genspera's Mipsagargin Phase 2 Results Impress
Austrolib - at Seeking Alpha - Tue Feb 24, 8:38AM CST
GenSpera Announces Partnership With Global Supplier
PR Newswire - Mon Feb 09, 7:00AM CST
GenSpera, Inc. (OTCQB: GNSZ) today announced a strategic partnership with Phyton Biotech for the manufacture of thapsigargin, which is derived from the thapsia plant and is the key ingredient in the company's investigational agent mipsagargin. Phyton Biotech will offer its Plant Cell Fermentation (PCF®) development expertise to convert the thapsia plant into a preserved, fermentable cell line with a goal of creating a sustainable source of high quality thapsigargin.
GenSpera Presents at BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 7:00AM CST
GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 17th Annual BIO CEO & Investor Conference on February 9th at 1 p.m. at the Waldorf Astoria in New York City. The presentation comes as GenSpera continues clinical development of mipsagargin for several tumor types and expands the applicability of its innovative mechanism of action in a broad array of oncology treatments.
GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin
PR Newswire - Fri Jan 16, 7:30AM CST
GenSpera Inc. (OTCQB: GNSZ) today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). The results will be presented today (12:00 to 2:00 p.m. PST, Abstract #301) in a poster presentation at the 2015 Gastrointestinal Cancers Symposium in San Francisco, California.
GenSpera Presents at Noble Financial Conference
PR Newswire - Tue Jan 13, 3:15PM CST
GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today that Craig A. Dionne, Ph.D., chief executive officer at GenSpera, will present on Monday, January 19, at 12:30 pm EST at the Noble Financial Capital Markets' Eleventh Annual Equity Conference in Sandpiper Bay, Florida.
GenSpera Announces New Digital Channels for Corporate Communications
PR Newswire - Thu Jan 08, 7:00AM CST
GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The company has established official portals on social media channels including: Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.
GenSpera Names JPA Health Communications as Its Agency of Record
PR Newswire - Tue Jan 06, 9:58AM CST
GenSpera, Inc., (OTCQB: GNSZ), a San Antonio based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announced today that it has named JPA Health Communications as its public relations agency of record.
GenSpera Inc. - "Glioblastoma Trial Design"
ACCESSWIRE - Thu May 14, 11:05AM CDT
NEW YORK, NY / ACCESSWIRE / May 14, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin
PR Newswire - Wed May 13, 7:09AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today the successful completion of the first stage of an ongoing Phase II study of its lead investigational agent, mipsagargin (G-202), in glioblastoma (brain cancer) and the continuation of enrollment for an expansion phase of the trial. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, Calif., and will evaluate the efficacy, safety and central nervous system (CNS) exposure in patients with recurrent or progressive glioblastoma.
GenSpera Provides Corporate Update
PR Newswire - Mon May 11, 8:03AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today reported its financial results for the three months ended March 31, 2015, and is providing the following corporate update to its shareholders to highlight the company's extensive organizational advances and clinical progress in the first quarter of 2015. GenSpera continues to unlock conventional thinking to conceive, design and develop cancer therapies. GenSpera's unique technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors.
GenSpera Inc. - "Value and Understanding What is Valuable Over Time"
ACCESSWIRE - Thu May 07, 10:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 7, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Dr. Craig A. Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations
PR Newswire - Wed May 06, 8:13AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that the patent application "Injectable Cancer Compositions" has entered the national phase application process in 17 countries and regions, including Europe, Eurasia, Japan, China, Brazil and the United States. When awarded, the resulting patent application will extend the exclusivity period for GenSpera's core intellectual property around its entire platform technology, including its lead drug candidate, mipsagargin, until 2033.
GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen
PR Newswire - Tue Apr 28, 7:10AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,957,016. This patent expands GenSpera's intellectual property portfolio claiming numerous compositions for the company's prodrugs designed to be activated by Prostate Specific Antigen (PSA).
GenSpera Looks Undervalued Compared to Its Peers
ACCESSWIRE - Mon Apr 27, 10:53AM CDT
CORAL GABLES, FL / ACCESSWIRE / April 27, 2015 / For clinical stage biotechs, valuations can be based on hype, speculation, attention from the press or any similar fortuitous circumstance. The only semi-concrete things to go on for price discovery of these securities sweeping financials aside and speaking in broad strokes, are 1) clinical milestones reached (or in other words, chances of eventual approval), 2) potential market size of the approved drug.
CYTR: 4.10 (-0.01), BIND: 5.92 (-0.32), NDRM: 13.10 (-0.01)
GenSpera Inc. - "Recap: Takeaways from Bio Asia"
ACCESSWIRE - Fri Apr 24, 10:10AM CDT
NEW YORK, NY / ACCESSWIRE / April 24, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Dr. Craig A. Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Contends In The Prodrug Space, Reaching Phase 3
Mayer Winkler - at Seeking Alpha - Mon Mar 30, 1:37PM CDT
GenSpera Launches National Investor Relations Program
PR Newswire - Mon Mar 30, 7:10AM CDT
GenSpera Inc. (OTCQB: GNSZ) announced today the selection of PCG Advisory Group (PCG) to launch a comprehensive investor relations initiative for the oncology-focused drug development company. Led by Jeff Ramson, founder and chief executive officer, the PCG team will also be directed by three senior members: Kirin Smith, COO and managing director of investor relations; Jeffrey Hart, managing director of market intelligence; and Sean Leous, CCO. The team will be supported by Carl Mauch, science analyst.
MarketExclusive.com - H.C. Wainwright & Co. Reiterates BUY Rating of GenSpera
ACCESSWIRE - Tue Mar 24, 9:48AM CDT
NEW YORK, NY / ACCESSWIRE / March 24, 2015 / Market Exclusive announces that H.C. Wainwright & Co. continues to rate the shares of GenSpera, Inc. (OTCQB: GNSZ) as Buy with a 12-month price target of $2.00 per share.
GenSpera Inc. - "Why China Matters to GenSpera"
ACCESSWIRE - Mon Mar 23, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / March 23, 2015 / GenSpera Inc. (OTCQB:GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Presents at BIO Asia International Conference
PR Newswire - Tue Mar 17, 7:00AM CDT
GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 12th Annual BIO Asia International Conference on Tuesday, March 24 at 3:15 p.m. JST at the Grand Hyatt in Tokyo, Japan. The presentation will offer an overview of the latest scientific developments of GenSpera's lead investigational agent mipsagargin and the applicability of its innovative mechanism of action in a broad array of oncology treatments.
Genspera's Mipsagargin Phase 2 Results Impress
Austrolib - at Seeking Alpha - Tue Feb 24, 8:38AM CST
GenSpera Announces Partnership With Global Supplier
PR Newswire - Mon Feb 09, 7:00AM CST
GenSpera, Inc. (OTCQB: GNSZ) today announced a strategic partnership with Phyton Biotech for the manufacture of thapsigargin, which is derived from the thapsia plant and is the key ingredient in the company's investigational agent mipsagargin. Phyton Biotech will offer its Plant Cell Fermentation (PCF®) development expertise to convert the thapsia plant into a preserved, fermentable cell line with a goal of creating a sustainable source of high quality thapsigargin.
GenSpera Presents at BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 7:00AM CST
GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 17th Annual BIO CEO & Investor Conference on February 9th at 1 p.m. at the Waldorf Astoria in New York City. The presentation comes as GenSpera continues clinical development of mipsagargin for several tumor types and expands the applicability of its innovative mechanism of action in a broad array of oncology treatments.
GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin
PR Newswire - Fri Jan 16, 7:30AM CST
GenSpera Inc. (OTCQB: GNSZ) today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). The results will be presented today (12:00 to 2:00 p.m. PST, Abstract #301) in a poster presentation at the 2015 Gastrointestinal Cancers Symposium in San Francisco, California.
GenSpera Presents at Noble Financial Conference
PR Newswire - Tue Jan 13, 3:15PM CST
GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today that Craig A. Dionne, Ph.D., chief executive officer at GenSpera, will present on Monday, January 19, at 12:30 pm EST at the Noble Financial Capital Markets' Eleventh Annual Equity Conference in Sandpiper Bay, Florida.
GenSpera Announces New Digital Channels for Corporate Communications
PR Newswire - Thu Jan 08, 7:00AM CST
GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The company has established official portals on social media channels including: Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.
GenSpera Names JPA Health Communications as Its Agency of Record
PR Newswire - Tue Jan 06, 9:58AM CST
GenSpera, Inc., (OTCQB: GNSZ), a San Antonio based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announced today that it has named JPA Health Communications as its public relations agency of record.
